Extracellular RNA

Extracellular RNA (also known as exRNA or exosomal RNA) describes RNA species present outside of the cells from which they were transcribed. In Homo sapiens, exRNAs have been discovered in bodily fluids such as venous blood, saliva, breast milk, urine, semen, menstrual blood, and vaginal fluid.[1][2][3][4][5][6] Although their biological function is not fully understood, exRNAs have been proposed to play a role in a variety of biological processes including syntrophy, intercellular communication, and cell regulation.[7][8] Due to their potential biological and clinical significance, the National Institutes of Health published in 2012 a Request for Applications (RFA) for investigating extracellular RNA biology.[9] The Extracellular Communication program is supported by the NIH Common Fund, and offers grants towards exRNA based research.

Background

A cartoon representation of the environments in which extracellular RNAs have been discovered.

Both prokaryotic and eukaryotic cells are known to secrete RNA. The Endosomal Sorting Complex Required for Transport (ESCRT) machinery was previously considered as a possible mechanism for RNA secretion from the cell, but more recently research studying microRNA secretion in human embryonic kidney cells and Cercopithecus aethiops kidney cells identified neutral sphingomyelinase 2 (nSMase2), an enzyme involved in ceramide biosynthesis, as a regulator of microRNA secretion levels.[7][8] ExRNAs are often found packaged within vesicles such as exosomes, ectosomes, prostasomes, microvesicles, and apoptotic bodies.[10][11][12][13] Although RNAs can be excreted from the cell without an enveloping container, ribonucleases present in extracellular environments would eventually degrade the molecule.

Types of ExRNA

Extracellular RNA should not be viewed as a category describing a set of RNAs with a specific biological function or belonging to a particular RNA family. Similar to the term "non-coding RNA", "extracellular RNA" defines a group of several types of RNAs whose functions are diverse, yet they share a common attribute which, in the case of exRNAs, is existence in an extracellular environment. The following types of RNA have been found outside the cell:

Though prevalent inside of the cell, ribosomal RNA (rRNA) does not seem to be a common exRNA. Efforts by Valadi et al. to characterize exosomal RNA using the Agilent Bioanalyzer technology showed little to no trace of 18S and 28S rRNA in exosomes secreted by MC/9 murine mast cells,[14] and similar conclusions were made by Skog et al. for rRNA in gliobastoma microvesicles.[15]

Function

To successfully function in extracellular environments, exRNA is often enclosed within a vesicular body to prevent its digestion by RNases. In some cases such as its use in prokaryotic syntrophy, exRNA is not packaged because the recipient cells use the ribnonuclease-digested nucleotides.[7] The use of extracellular vesicles to protect exRNA from degradation is believed to be linked with the use of these containers as a way to transport RNA between cells. Biochemical evidence supports the idea that exRNA uptake is a common process, suggesting new pathways for intercellular communication. As a result, the presence, absence, and relative abundance of certain exRNAs can be correlated with changes in cellular signaling and may indicate specific disease states.[16]

Despite a limited understanding of exRNA biology, current research has shown the role of exRNAs to be multi-faceted.[16][17][18][19][20] Extracellular miRNAs are capable of targeting mRNAs in the recipient cell through RNA interference pathways.[8][21] In vitro experiments have shown the transfer of specific exRNAs into recipient cells inhibiting protein expression and preventing cancer cell growth.[22] In addition to mRNAs being regulated by exRNAs, mRNAs can act as exRNAs to carry genetic information between cells. Messenger RNA contained in microvesicles secreted from glioblastomal cells were shown to generate a functional protein in recipient (human brain microvascular endothelial) cells in vitro. In another study of extracellular mRNAs, mRNAs transported by microvesicles from endothelial progenitor cells (EPCs) to human microvascular and macrovascular endothelial cells triggered angiogenesis in both the in vitro and in vivo setting.[10][23] Work by Hunter et al. used Ingenuity Pathway Analysis (IPA) software that associated exRNAs found in human blood microvesicles with pathways involved in blood cell differentiation, metabolism, and immune function.[24] These experimental and bioinformatics analyses favor the hypothesis that exRNAs play a role in numerous biological processes.

ExRNA Detection

Several methods have been developed or adapted to detect, characterize, and quantify exRNA from biological samples. RT-PCR, cDNA microarrays, and RNA sequencing are common techniques for RNA analysis. Applying these methods to study exRNAs mainly differs from cellular RNA experiments in the RNA isolation and/or extraction steps.

RT-PCR

For known exRNA nucleotide sequences, RT-PCR can be applied to detect their presence within a sample as well as quantify their abundance. This is done through first reverse transcribing the RNA sequence into cDNA. The cDNA then serves as a template for PCR amplification. The major benefits of using RT-PCR are its quantitative accuracy in a dynamic range and increased sensitivity compared to methods such as RNase protection assays and dot blot hybridization. The disadvantage to RT-PCR is the requirement of costly supplies, and the necessity of sound experimental design and an in-depth understanding of normalization techniques in order to obtain accurate results and conclusions.[25]

Microfluidics

Microfluidic platforms such as the Agilent Bioanalyzer are useful in assessing the quality of exRNA samples. With the Agilent Bioanalyzer, a lab-on-chip technology that uses a sample of isolated RNA measures the length and quantity of RNA in the sample, and the results of the experiment can be represented as a digital electrophoresis gel image or an electropherogram. Because a diverse range of RNAs can be detected by this technology, it is an effective method for more generally determining what types of RNAs are present in exRNAs samples through using size characterization.

cDNA Microarrays

Microarrays allow for larger-scale exRNA characterization and quantification. Microarrays used for RNA studies first generate different cDNA oligonucleotides (probes) that are attached to the microarray chip. An RNA sample can then be added to the chip, and RNAs with sequence complementarity to the cDNA probe will bind and generate a fluorescent signal that can be quantified. Micro RNA arrays have been used in exRNA studies to generate miRNA profiles of bodily fluids.[16][26]

RNA Sequencing

The advent of massively parallel sequencing (next-generation sequencing) lead to variations in DNA sequencing that allowed for high-throughput analyses of many genomic properties. Among these DNA sequencing-derived methods is RNA sequencing. The main advantage of RNA sequencing over other methods for exRNA detection and quantification is its high-throughput capabilities. Unlike microarrays, RNA sequencing is not constrained by factors such as oligonucleotide generation, and the number of probes that can be added to a chip. Indirect RNA sequencing of exRNA samples involves generating a cDNA library from the exRNAs followed by PCR amplification and sequencing. In 2009, Helicos Biosciences published a method for directly sequencing RNA molecules called Direct RNA sequencing (DRS™).[27] Regardless of the RNA sequencing platform, inherent biases exist at various steps in the experiment, but methods have been proposed to correct for these biases with promising results.[28][29]

Clinical Significance

As growing evidence supports the function of exRNAs as intercellular communicators, research efforts are investigating the possibility of utilizing exRNAs in disease diagnosis, prognosis, and therapeutics.[1][30]

Biomarkers

The potential of extracellular RNAs to serve as biomarkers is significant not only because of their role in intercellular signaling but also due to developments in next generation sequencing that enable high throughput profiling.[31][32] The simplest form of an exRNA biomarker is the presence (or absence) of a specific extracellular RNA. These biological signatures have been discovered in exRNA studies of cancer, diabetes, arthritis, and prion-related diseases.[1][16][33]

Cancer

A major research area of interest for exRNA has been its role in cancer. The table below (adapted from Kosaka et al.[21]) lists several types of cancer in which exRNAs have been shown to be associated:

Cancer Type ExRNA Biomarker Candidate
Diffuse large B-cell lymphoma (DLBCL) Expression levels of miR-155, miR-210 and miR-21 were higher in DLBCL patient sera compared to control sera; High miR-21 expression was associated with relapse-free survival
Prostate cancer Serum levels of miR-141 can distinguish patients with prostate cancer from healthy controls
Ovarian cancer The levels of the 8 specific miRNAs were similar between cellular and exosomal miRNAs. Exosomal miRNA from ovarian cancer patients exhibited similar profiles, which were significantly distinct from profiles observed in benign disease; miR-21, miR-92, miR-93, miR-126 and miR-29a were significantly overexpressed in

the serum from cancer patients compared to controls

Non small cell lung cancer Eleven serum miRNAs were found to be altered more than 5-fold between longer-survival and shorter-survival groups, and levels of four miRNAs were significantly associated with overall survival
Acute myeloid leukemia and acute lymphoblastic leukemia miR-92a decreased in the plasmas of acute leukemia patients
Breast cancer Increased miR-195 levels in patients were reflected in tumors, and circulating levels of miR-195 and let-7a decreased in cancer patients postoperatively, to levels comparable with control subjects; miR-155 was differentially expressed in the serum of women with hormone-sensitive compared to women with hormone-insensitive

breast cancer

Gastric cancer The plasma concentrations of miR-17-5p, miR-21, miR-106a, and miR-106b were significantly higher in patients than controls,whereas let-7a was lower in patients
Pancreatic cancer Circulating miR-210 levels are elevated in pancreatic cancer patients
Pancreatic ductal adenocarcinoma The combined analyses of four miRNAs (miR-21, miR-210, miR-155, and miR-196a) in plasma can discriminate patients from normal healthy individuals
Squamous cell carcinoma (SCC) of tongue Plasma miR-184 levels were significantly higher in tongue SCC patients in comparison with normal individuals, and the levels were significantly reduced after surgical removal of the primary tumors
Colorectal cancer Both miR-17-3p and miR-92 were significantly elevated in the patients, and the plasma levels of these miRNAs were reduced after surgery
Hepatocellular carcinoma (HCC) An increased amount of miR-500 was found in the sera of the HCC patients, and its levels in sera returned to normal after the surgical treatment

See also

References

  1. 1 2 3 Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY (October 2008). "Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.". Cell research. 18 (10): 997–1006. doi:10.1038/cr.2008.282. PMID 18766170.
  2. ↑ Michael, A; Bajracharya, SD; Yuen, PS; Zhou, H; Star, RA; Illei, GG; Alevizos, I (January 2010). "Exosomes from human saliva as a source of microRNA biomarkers.". Oral diseases. 16 (1): 34–8. doi:10.1111/j.1601-0825.2009.01604.x. PMC 2844919Freely accessible. PMID 19627513.
  3. ↑ Kosaka, N; Izumi, H; Sekine, K; Ochiya, T (Mar 1, 2010). "microRNA as a new immune-regulatory agent in breast milk.". Silence. 1 (1): 7. doi:10.1186/1758-907X-1-7. PMC 2847997Freely accessible. PMID 20226005.
  4. ↑ Menke, TB; Warnecke, JM (June 2004). "Improved conditions for isolation and quantification of RNA in urine specimens.". Annals of the New York Academy of Sciences. 1022: 185–9. doi:10.1196/annals.1318.028. PMID 15251958.
  5. ↑ Zubakov D, Boersma AW, Choi Y, van Kuijk PF, Wiemer EA, Kayser M (May 2010). "MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation.". International journal of legal medicine. 124 (3): 217–26. doi:10.1007/s00414-009-0402-3. PMC 2855015Freely accessible. PMID 20145944.
  6. ↑ Hanson, EK; Lubenow, H; Ballantyne, J (Apr 15, 2009). "Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs.". Analytical Biochemistry. 387 (2): 303–14. doi:10.1016/j.ab.2009.01.037. PMID 19454234.
  7. 1 2 3 Demain, AL; Burg, RW; Hendlin, D (March 1965). "Excretion and Degradation of Ribonucleic Acid by Bacillus Subtilis.". Journal of Bacteriology. 89: 640–6. PMC 277514Freely accessible. PMID 14273638.
  8. 1 2 3 Iguchi, H; Kosaka, N; Ochiya, T (September 2010). "Secretory microRNAs as a versatile communication tool.". Communicative & integrative biology. 3 (5): 478–81. doi:10.4161/cib.3.5.12693. PMC 2974086Freely accessible. PMID 21057646.
  9. ↑ NIH, USA. "NIH Common Fund RFA for exRNA Communication". Retrieved 7 November 2012.
  10. 1 2 Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G (Oct 1, 2007). "Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA.". Blood. 110 (7): 2440–8. doi:10.1182/blood-2007-03-078709. PMID 17536014.
  11. ↑ Wolfers, J; Lozier, A; Raposo, G; Regnault, A; Théry, C; Masurier, C; Flament, C; Pouzieux, S; Faure, F; Tursz, T; Angevin, E; Amigorena, S; Zitvogel, L (March 2001). "Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.". Nature Medicine. 7 (3): 297–303. doi:10.1038/85438. PMID 11231627.
  12. ↑ Babiker, AA; Nilsson, B; Ronquist, G; Carlsson, L; Ekdahl, KN (Feb 1, 2005). "Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack.". The Prostate. 62 (2): 105–14. doi:10.1002/pros.20102. PMID 15389819.
  13. ↑ Holmgren, L; Szeles, A; Rajnavölgyi, E; Folkman, J; Klein, G; Ernberg, I; Falk, KI (Jun 1, 1999). "Horizontal transfer of DNA by the uptake of apoptotic bodies.". Blood. 93 (11): 3956–63. PMID 10339505.
  14. ↑ Valadi, H; Ekström, K; Bossios, A; Sjöstrand, M; Lee, JJ; Lötvall, JO (June 2007). "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.". Nature Cell Biology. 9 (6): 654–9. doi:10.1038/ncb1596. PMID 17486113.
  15. ↑ Noerholm, M; Balaj, L; Limperg, T; Salehi, A; Zhu, LD; Hochberg, FH; Breakefield, XO; Carter, BS; Skog, J (Jan 17, 2012). "RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls.". BMC Cancer. 12: 22. doi:10.1186/1471-2407-12-22. PMC 3329625Freely accessible. PMID 22251860.
  16. 1 2 3 4 Bellingham, SA; Coleman, BM; Hill, AF (November 2012). "Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells.". Nucleic Acids Research. 40 (21): 10937–49. doi:10.1093/nar/gks832. PMC 3505968Freely accessible. PMID 22965126.
  17. ↑ Iguchi, H; Kosaka, N; Ochiya, T (June 2010). "Versatile applications of microRNA in anti-cancer drug discovery: from therapeutics to biomarkers.". Current drug discovery technologies. 7 (2): 95–105. PMID 20836759.
  18. ↑ Bellingham, SA; Guo, BB; Coleman, BM; Hill, AF (2012). "Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?". Frontiers in Physiology. 3: 124. doi:10.3389/fphys.2012.00124. PMC 3342525Freely accessible. PMID 22563321.
  19. ↑ Coleman, BM; Hanssen, E; Lawson, VA; Hill, AF (October 2012). "Prion-infected cells regulate the release of exosomes with distinct ultrastructural features.". FASEB Journal. 26 (10): 4160–73. doi:10.1096/fj.11-202077. PMID 22767229.
  20. ↑ Hessvik, NP; Phuyal, S; Brech, A; Sandvig, K; Llorente, A (November 2012). "Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells.". Biochimica et Biophysica Acta. 1819 (11-12): 1154–63. doi:10.1016/j.bbagrm.2012.08.016. PMID 22982408.
  21. 1 2 Kosaka, N; Iguchi, H; Ochiya, T (October 2010). "Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis.". Cancer science. 101 (10): 2087–92. doi:10.1111/j.1349-7006.2010.01650.x. PMID 20624164.
  22. ↑ Kosaka, N; Iguchi, H; Yoshioka, Y; Takeshita, F; Matsuki, Y; Ochiya, T (Jun 4, 2010). "Secretory mechanisms and intercellular transfer of microRNAs in living cells.". The Journal of Biological Chemistry. 285 (23): 17442–52. doi:10.1074/jbc.M110.107821. PMC 2878508Freely accessible. PMID 20353945.
  23. ↑ Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT, Carter BS, Krichevsky AM, Breakefield XO (December 2008). "Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.". Nature Cell Biology. 10 (12): 1470–6. doi:10.1038/ncb1800. PMC 3423894Freely accessible. PMID 19011622.
  24. ↑ Hunter, MP; Ismail, N; Zhang, X; Aguda, BD; Lee, EJ; Yu, L; Xiao, T; Schafer, J; Lee, ML; Schmittgen, TD; Nana-Sinkam, SP; Jarjoura, D; Marsh, CB (2008). "Detection of microRNA expression in human peripheral blood microvesicles.". PLoS ONE. 3 (11): e3694. doi:10.1371/journal.pone.0003694. PMC 2577891Freely accessible. PMID 19002258.
  25. ↑ Wong, ML; Medrano, JF (July 2005). "Real-time PCR for mRNA quantitation.". BioTechniques. 39 (1): 75–85. doi:10.2144/05391rv01. PMID 16060372.
  26. ↑ Turchinovich, A; Weiz, L; Langheinz, A; Burwinkel, B (Sep 1, 2011). "Characterization of extracellular circulating microRNA.". Nucleic Acids Research. 39 (16): 7223–33. doi:10.1093/nar/gkr254. PMC 3167594Freely accessible. PMID 21609964.
  27. ↑ Ozsolak, F; Platt, AR; Jones, DR; Reifenberger, JG; Sass, LE; McInerney, P; Thompson, JF; Bowers, J; Jarosz, M; Milos, PM (Oct 8, 2009). "Direct RNA sequencing.". Nature. 461 (7265): 814–8. doi:10.1038/nature08390. PMID 19776739.
  28. ↑ Dillies MA, Rau A, Aubert J, Hennequet-Antier C, Jeanmougin M, Servant N, Keime C, Marot G, Castel D, Estelle J, Guernec G, Jagla B, Jouneau L, Laloë D, Le Gall C, Schaëffer B, Le Crom S, Guedj M, Jaffrézic F (Sep 17, 2012). "A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis.". Briefings in bioinformatics. 14: 671–683. doi:10.1093/bib/bbs046. PMID 22988256.
  29. ↑ Wang, Z; Gerstein, M; Snyder, M (January 2009). "RNA-Seq: a revolutionary tool for transcriptomics.". Nature Reviews Genetics. 10 (1): 57–63. doi:10.1038/nrg2484. PMC 2949280Freely accessible. PMID 19015660.
  30. ↑ Thind A, Wilson C (2016). "Exosomal miRNAs as cancer biomarkers and therapeutic targets.". J Extracell Vesicles. 19 (5): 31292. doi:10.3402/jev.v5.31292. PMID 27440105.
  31. ↑ Cloonan, N; Xu, Q; Faulkner, GJ; Taylor, DF; Tang, DT; Kolle, G; Grimmond, SM (Oct 1, 2009). "RNA-MATE: a recursive mapping strategy for high-throughput RNA-sequencing data.". Bioinformatics (Oxford, England). 25 (19): 2615–6. doi:10.1093/bioinformatics/btp459. PMC 2752615Freely accessible. PMID 19648138.
  32. ↑ Majewski, J; Pastinen, T (February 2011). "The study of eQTL variations by RNA-seq: from SNPs to phenotypes.". Trends in genetics : TIG. 27 (2): 72–9. doi:10.1016/j.tig.2010.10.006. PMID 21122937.
  33. ↑ Murata, K; Yoshitomi, H; Tanida, S; Ishikawa, M; Nishitani, K; Ito, H; Nakamura, T (2010). "Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis". Arthritis Research & Therapy. 12 (3): R86. doi:10.1186/ar3013. PMC 2911870Freely accessible. PMID 20470394.

External links

This article is issued from Wikipedia - version of the 8/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.